Assessment of oral bioavailability enhancing approaches for SB-247083 using flow-through cell dissolution testing as one of the screens.

Perng, Cherng-Yih; Kearney, Albert S; Palepu, Nagesh R; Smith, Brian R; Azzarano, Leonard M

Perng, Cherng-Yih; Kearney, Albert S; Palepu, Nagesh R; Smith, Brian R; Azzarano, Leonard M.

Affiliation

Perng CY; Pharmaceutical Development, GlaxoSmithKline plc, 709 Swedeland Road, King of Prussia, PA 19406, USA. david_perng-1@gsk.com

Int J Pharm ; 250(1): 147-56, 2003 Jan 02.

Article in En | MEDLINE | ID: mdl-12480281

Subject(s)

Benzofurans/pharmacokinetics; Endothelin Receptor Antagonists; Propionates/pharmacokinetics; Administration, Oral; Animals; Benzofurans/chemistry; Biological Availability; Dogs; Excipients; Male; Propionates/chemistry; Receptor, Endothelin A; Solubility

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Propionates / Benzofurans / Endothelin Receptor Antagonists Limits: Animals Language: En Journal: Int J Pharm Year: 2003 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links